

ASX Announcement
10 November 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Partners with ACL to Advance Digital Pathology

Optiscan Announces Strategic Collaboration with Australian Clinical Labs (ASX: ACL) to Accelerate Digital Pathology Innovation and Deployment.

Highlights

- Optiscan has signed a Collaboration Agreement with Australian Clinical Labs (ACL) to support the deployment and testing of its InForm™ digital pathology platform.
- ACL will provide access to its extensive laboratory network, enabling Optiscan to validate the InForm™ device in real-world conditions and collect imaging data from a broad range of human tissues and pathologies.
- Optiscan will test the InForm™ digital pathology device within ACL's flagship anatomical pathology laboratory in Western Australia.
- The collaboration supports pathologist training, regulatory submissions, and accelerates the wider adoption of digital pathology solutions, enhancing both Optiscan's technology and ACL's digital capabilities.
- The collaboration represents a major milestone in transforming pathology by allowing end-to-end real-time digital analysis of samples at the point of contact with tissue.

Optiscan Imaging Limited (ASX: OIL) ('Optiscan' or the 'Company') is pleased to announce a three-year Strategic Collaboration Agreement (the '**Agreement**') with Australian Clinical Labs Limited (ASX: ACL), a leading private provider of pathology services in Australia. This partnership marks a significant milestone in the deployment of real-time digital pathology workflows, leveraging Optiscan's InForm™ platform to transform diagnostic practices in pathology environments both in Australia and overseas. The Agreement will benefit both the commercial readiness of the InForm™ device and the preparatory work for subsequent regulatory submissions in Australia and in the US.

Agreement expedites delivery of InForm™ device image databank

The collaboration will enable Optiscan to validate its InForm™ digital pathology device in an active laboratory environment and build an image databank of human tissues and associated pathologies. This databank will be used to facilitate pathologist training and deployment of Optiscan's platform technology within anatomical pathology workflows across the sector. As a collaborating partner, ACL will have first access to the Company's catalogue of InForm™ digital pathology device-generated insights.

This partnership enables end-to-end, real-time digital analysis of tissue samples at the point of contact, streamlining workflows and improving diagnostic accuracy. As a leading provider of pathology services in

Australia, ACL has a network of 50 NATA accredited laboratories, 85 RCPA-accredited pathologists, 4,700 scientists, collectors and support staff, and 1,288 approved collection centres, which together serve a diverse range of clinicians and patients across the country. ACL is one of the largest Australian providers of hospital-based pathology services. Its extensive network and established pathology capability will enable Optiscan to accelerate real-world testing, refine imaging workflows, and optimise InForm™ for seamless integration across laboratory medicine, pathology practice, and point-of-care applications.

Agreement will help advance commercial readiness of InForm™

Optiscan will work alongside pathologists and technicians at ACL's flagship anatomical pathology laboratory in Western Australia to test InForm™ within an active anatomical pathology setting to ensure the device is optimised for real-time pathology workflows. This represents a major milestone in advancing commercial readiness of InForm™, collecting necessary imaging data for pathologist training, and subsequent regulatory submissions in Australia and in the US.

Optiscan CEO and Managing Director, Dr Camile Farah, said: "This three-year Collaboration Agreement with ACL comes with two clear-cut advantages that make it a real game-changer in the broader development and ultimately commercialisation strategies for our InForm™ digital pathology device. It gives us access to a fully operational pathology laboratory that will quicken the pace at which we validate the InForm™ device in real-world conditions, ensuring it meets the needs of healthcare sector professionals, pathologists and technicians. Then there is the regulatory approvals-related advantage delivered by the Agreement. It will help expediate our plans to build an image databank of human tissues and associated pathologies, a useful data collection resource that will be incorporated into preparatory work we are now undertaking for regulatory submissions in Australia and in the US.

Dr Farah added: Our stated goal has always been to revolutionise pathology by delivering real-time digital microscopic insights at point of care, and I want to personally thank ACL for sharing in this vision. I am confident that this Agreement will deliver outcomes that demonstrate the significant efficiencies in pathology services encapsulated in our digital solution. The Optiscan team looks forward to sharing the insights generated by the Collaboration Agreement, in the confidence it will help lay the groundwork for early adoption of our innovative medical technology by healthcare professionals both here and overseas."

ACL's Medical Director and Chief Pathologist, Associate Professor Tony Landgren, said: "We are excited to collaborate with Optiscan, highlighting our commitment to innovation and clinical excellence. This opportunity has the potential to enhance diagnostic workflows with real-time, data-driven insights — a move that supports faster, more accurate decision-making."

The Company will provide regular updates as key milestones are achieved throughout the collaboration.

— ends —

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au**About Optiscan**

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

About Australian Clinical Labs

Australian Clinical Labs (ACL) is a leading Australian private provider of pathology services. ACL is one of the largest private hospital pathology businesses nationally and in its established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia and the Northern Territory, has an equivalent market position in community pathology to Sonic Healthcare and Healius. ACL also has a growing presence in the Australian Capital Territory. ACL has a national footprint of 1,288 approved collection centres and 29 clinics to collect patient samples and operates 50 NATA accredited laboratories across Australia.

To learn more about ACL, visit www.clinicallabs.com.au

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.